The Ninth International Symposium on Myelodysplastic Syndromes

Florence, Italy
May 16-19, 2007

Chairman: Mario Cazzola
Dear Colleagues,

We have the great pleasure of welcoming you to the 9th International Symposium on Myelodysplastic Syndromes, which is being held in Florence, Italy, from May 16th to 19th, 2007, and is sponsored by the Myelodysplastic Syndromes Foundation. This meeting follows those of Innsbruck (1988), Bournemouth (1991), Chicago (1994), Barcelona (1997), Prague (1999), Stockholm (2001), Paris (2003) and Nagasaki (2005), which were all successful.

As in previous meetings, we have tried to cover all aspects of basic and clinical research, and have done our best to ensure that MDS 2007 provides a venue for discussion of the latest advances in our understanding of myelodysplastic syndromes. We have limited the space for invited lectures and have given more room to selected oral and poster presentations. Moreover, we have established awards for young investigators and have tried to involve as much as possible young scientists working both in basic and clinical research. The Symposium will also provide attendees with opportunities to earn continuing medical education credits within the European Hematology Association CME program.

Thank you very much for joining us in Florence and bringing your scientific work to the Symposium.

Mario Cazzola, Chairman
Alberto Bosi, Vice-Chairman
Cristina Mecucci, Vice-Chairwoman
Valeria Santini, Vice-Chairwoman
International Scientific Committee and Italian Scientific Committee

International Scientific Committee

John Bennett (Rochester, USA)
Jacqueline Boulwood (Oxford, United Kingdom)
David T. Bowen (Leeds, United Kingdom)
Consuelo del Cañizo (Salamanca, Spain)
Theo de Witte (Nijmegen, Netherlands)
Elihu Estey (Houston, USA)
Pierre Fenaux (Paris, France)
Michaela Fontenay (Paris, France)
Arnold Ganser (Hannover, Germany)
Guillermo Garcia-Manero (Houston, USA)
Norbert Gatterman (Düsseldorf, Germany)
Ulrich Germing (Düsseldorf, Germany)
Aristoteles A.N. Giagounidis (Duisburg, Germany)
Stuart L. Goldberg (Hackensack, USA)
Steven D. Gore (Baltimore, USA)
Peter Greenberg (Stanford, USA)
Terry Hamblin (Southampton, United Kingdom)
Eva Hellström-Lindberg (Stockholm, Sweden)
Heather A. Leitch (Vancouver, Canada)

Alan List (Tampa, USA)
Michael Lübbert (Freiburg, Germany)
Ghulam Mufti (London, United Kingdom)
Sucha Nand (Chicago, USA)
Charlotte M. Niemeyer (Freiburg, Germany)
Stephen D. Nimer (New York, USA)
Rose Ann Padua (Paris, France)
Jens Pedersen-Bjergaard (Copenhagen, Denmark)
Timothy E. Quill (Rocheester, USA)
Guillermo F. Sanz (Valencia, Spain)
Charles A. Schiffer (Detroit, USA)
John F. Seymour (Melbourne, Australia)
Lewis R. Silverman (New York, USA)
Radek Skoda (Basel, Switzerland)
David P. Steensma (Rochester, USA)
Masao Tomonaga (Nagasaki, Japan)
James S. Wainscoat (Oxford, United Kingdom)
Neal S. Young (Bethesda, USA)
Nicolaos C. Zoumbos (Patras, Greece)
# Italian Scientific Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mario Cazzola</td>
<td>Pavia</td>
</tr>
<tr>
<td>Alberto Bosi</td>
<td>Firenze</td>
</tr>
<tr>
<td>Cristina Mecucci</td>
<td>Perugia</td>
</tr>
<tr>
<td>Valeria Santini</td>
<td>Firenze</td>
</tr>
<tr>
<td>Emilio Paolo Alessandrino</td>
<td>Pavia</td>
</tr>
<tr>
<td>Sergio Amadori</td>
<td>Roma</td>
</tr>
<tr>
<td>Michele Baccarani</td>
<td>Bologna</td>
</tr>
<tr>
<td>Ercole Brusamolino</td>
<td>Pavia</td>
</tr>
<tr>
<td>Carlo Castagnola</td>
<td>Pavia</td>
</tr>
<tr>
<td>Gianluigi Castoldi</td>
<td>Ferrara</td>
</tr>
<tr>
<td>Antonio Cuneo</td>
<td>Ferrara</td>
</tr>
<tr>
<td>Matteo G. Della Porta</td>
<td>Pavia</td>
</tr>
<tr>
<td>Brunangelo Falini</td>
<td>Perugia</td>
</tr>
<tr>
<td>Felicetto Ferrara</td>
<td>Napoli</td>
</tr>
<tr>
<td>Robin Foà</td>
<td>Roma</td>
</tr>
<tr>
<td>Marco Gobbi</td>
<td>Genova</td>
</tr>
<tr>
<td>Alberto Grossi</td>
<td>Firenze</td>
</tr>
<tr>
<td>Rosangela Invernizzi</td>
<td>Pavia</td>
</tr>
<tr>
<td>Francesco Lauria</td>
<td>Siena</td>
</tr>
<tr>
<td>Mario Lazzarino</td>
<td>Pavia</td>
</tr>
<tr>
<td>Giuseppe Leone</td>
<td>Roma</td>
</tr>
<tr>
<td>Pietro Leoni</td>
<td>Ancona</td>
</tr>
<tr>
<td>Alessandro Levis</td>
<td>Alessandria</td>
</tr>
<tr>
<td>Lucio Luzzatto</td>
<td>Firenze</td>
</tr>
<tr>
<td>Luca Malcovati</td>
<td>Pavia</td>
</tr>
<tr>
<td>Enrica Morra</td>
<td>Milano</td>
</tr>
<tr>
<td>Pellegrino Musto</td>
<td>Rionero in Vulture</td>
</tr>
<tr>
<td>Mario Petrini</td>
<td>Pisa</td>
</tr>
<tr>
<td>Giovanni Pizzolo</td>
<td>Verona</td>
</tr>
<tr>
<td>PierLuigi Rossi Ferrini</td>
<td>Firenze</td>
</tr>
<tr>
<td>Bruno Rotoli</td>
<td>Napoli</td>
</tr>
<tr>
<td>Giuseppe Torelli</td>
<td>Modena</td>
</tr>
<tr>
<td>Sante Tura</td>
<td>Bologna</td>
</tr>
<tr>
<td>Alberto Zanella</td>
<td>Milano</td>
</tr>
<tr>
<td>DAY</td>
<td>TIME</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>WEDNESDAY 16</td>
<td>16:00 - 19:00</td>
</tr>
<tr>
<td></td>
<td>19:00</td>
</tr>
<tr>
<td>THURSDAY 17</td>
<td>08:30 - 10:00</td>
</tr>
<tr>
<td></td>
<td>10:00 - 10:30</td>
</tr>
<tr>
<td></td>
<td>10:30 - 12:00</td>
</tr>
<tr>
<td></td>
<td>12:00 - 13:30</td>
</tr>
<tr>
<td></td>
<td>13:30 - 14:30</td>
</tr>
<tr>
<td></td>
<td>14:30 - 16:00</td>
</tr>
<tr>
<td></td>
<td>16:00 - 18:00</td>
</tr>
<tr>
<td></td>
<td>18:00 - 19:30</td>
</tr>
<tr>
<td>TIME</td>
<td>LOCATION</td>
</tr>
<tr>
<td>------</td>
<td>----------</td>
</tr>
<tr>
<td>FRIDAY 18</td>
<td>AUDITORIUM</td>
</tr>
<tr>
<td>8:30 - 10:00</td>
<td>PALAFFARI 2nd floor</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>PASSI PERDUTI</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>PASI PERDUTI</td>
</tr>
<tr>
<td>12:00 - 13:30</td>
<td>PASI PERDUTI</td>
</tr>
<tr>
<td>13:30 - 14:30</td>
<td>PALAFFARI ground and 1st floor</td>
</tr>
<tr>
<td>14:30 - 15:30</td>
<td>PALAFFARI ground and 1st floor</td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>PALAFFARI ground and 1st floor</td>
</tr>
<tr>
<td>16:00 - 18:00</td>
<td>PALAFFARI ground and 1st floor</td>
</tr>
<tr>
<td>18:00 - 19:30</td>
<td>PASI PERDUTI</td>
</tr>
<tr>
<td>SATURDAY 19</td>
<td>AUDITORIUM</td>
</tr>
<tr>
<td>8:30 - 10:30</td>
<td>PASI PERDUTI</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>PALAFFARI 2nd floor</td>
</tr>
<tr>
<td>11:00 - 12:45</td>
<td>PASSI PERDUTI</td>
</tr>
</tbody>
</table>
The Ninth International Symposium on Myelodysplastic Syndromes

Florence, Italy
May 16-19, 2007
Wednesday, May 16, 2007

AUDITORIUM

16:00-19.00 Opening Lectures on Myelodysplastic Syndromes
Chairmen: P. Greenberg, M. Tomonaga

16:00-16:45 Epidemiologic features of myelodysplastic syndromes
U. Germing

16:45-17:30 Classification of primary myelodysplastic syndromes
J. Bennett

17:30-18:15 Therapy-related myelodysplasia
J. Pedersen-Bjergaard

18:15-19:00 Susanne Fleischman Memorial Lecture: Communicating evidence for participatory decision making
T.E. Quill

AUDITORIUM

19:00 Opening Ceremony
John Bennett, Peter Greenberg: MDS 2007
Young Investigator “Tito Bastianello” Awards

AMMANNATI COURTYARD (Palazzo Pitti)

19:45 Welcome Reception
Thursday, May 17, 2007

AUDITORIUM

8:30-10:00  **Molecular Basis and Pathophysiology of Myelodysplastic Syndromes (I)**
Chairman: T. Hamblin

- 8:30-9:00  Animal models of myelodysplasia  
  R.A. Padua
- 9:00-9:30  Acquired thalassemia in myelodysplastic syndrome: rare curiosity, or revealing condition?  
  D. Steensma
- 9:30-10:00  The immune pathophysiology of bone marrow failure and the emergence of clonal hematologic diseases  
  N.S. Young

EXHIBITION AREA

10:00-10:30  Coffee Break

AUDITORIUM

10:30-12:00  **Molecular Basis and Pathophysiology of Myelodysplastic Syndromes (II)**
Chairwoman: C. Niemeyer

- 10:30-11:00  Molecular analysis of the 5q- syndrome  
  J. Boultwood
11:00-11:30  Refractory anemia with ringed sideroblasts  
M. Cazzola

11:30-12:00  Insights into the molecular pathogenesis of myelodysplastic syndromes  
S.D. Nimer

**AUDITORIUM**

**12:00-13:30  Symposium on Multi-Targeted Therapy of Myelodysplastic Syndromes and Acute Myeloid Leukemia (sponsored by Pharmion)**

Chairman: M. Baccarani

12:00-12:20  DNA methyltransferase inhibition in the therapy of myelodysplastic syndromes  
V. Santini

12:20-12:40  Combination epigenetic therapy  
G. Garcia-Manero

12:40-13:00  Treatment of myelodysplastic syndromes with azacitidine and thalidomide  
J.F. Seymour

13:00-13:20  Treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly with azacitidine and gemtuzumab ozogamicin  
S. Nand

13:20-13:30  Conclusions  
M. Baccarani
13:30-14:30  Open time for lunch

**AUDITORIUM**

**14:30-16:00 Symposium on Lenalidomide - Changing the MDS Treatment Paradigm (sponsored by Celgene)**
Chairmen: P. Fenaux, E. Morra

14:30-14:35  Introduction
E. Morra

14:35-14:55  Cytogenetics of myelodysplastic syndromes and detection of del 5q
G. Mufti

14:55-15:15  Active treatment - improving outcome in del 5q patients
A. List

15:15-15:30  Treating non-del 5q patients with lenalidomide
C. Schiffer

15:30-15:45  Practical management of lenalidomide
A.A. Giagounidis

15:45-16:00  The MDS treatment paradigm - time for a change?
Panel discussion/challenging debate
Moderator: P. Fenaux

16:00-18:00  Simultaneous Oral Sessions
SESSION I: Epidemiology and Classification

Chairmen: A. Cuneo, G. Leone

C001
Estimating the prevalence and pre-test likelihood of myelodysplasia: A retrospective review of bone marrow histopathology in 322 cases of unexplained cytopenia(s) in a teaching Hospital.
R. Buckstein, K. Jang, A. Chesney, MD Reis, J. Friedlich, L. Zhang, RA. Wells.
MDS Program, Medical Oncology/Hematology and Hematopathology, Toronto Sunnybrook Regional Cancer Center (TSRCC), Toronto, ON, Canada

C002
Polymorphisms of DNA-repair and detoxification enzymes in myelodysplastic syndromes.
Istituto di Ematologia, Universita’ Cattolica S. Cuore, Roma, Italy

C003
A molecular classification of leukaemia reveals MDS as a disease continuum with non-leukaemia and AML sub groups.
A.F. Gilkes, K.L. Mills, J.M. Hernandez, W-K. Hofmann, A. Kohlmann, M. Williams, L. Wieczorek, T. Haferlach Department of Haematology, Cardiff, United Kingdom; CCRCB, Queens University Belfast, United Kingdom, MLL Munich Leukemia Laboratory, Munich, Germany; Hematología, Salamanca, Spain; Charité, Berlin, Germany

C004
Proposals of division for diagnostic accuracy in myelodysplastic syndromes.
A. Matsuda, I. Jinnai, K. Araseki, T. Hata, M. Bessho, M. Tomonaga
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan. Department of Hematology, Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

C005
New definitions for blast cells in AML and MDS with validation by virtual microscopy.
J.E. Goasguen, J.M. Bennett, B. Bain, R. Brunning, M.T. Vallespi, C. Cox, G. Mufti
From International Working Group on MDS (IWG on MDS)
C006
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.
Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf; Department of Hematology, Oncology and Clinical Immunology. St. Johannes Hospital, Duisburg, Germany

C007
Chronic myelomonocytic leukemia (CMML) and CD4+/CD56+ plasmacytoid leukemia are two different phenotypic entities.
C. Martel, C. Lacronique-Gazaille, M-P. Chaury, J-L. Faucher, D. Bordessoule, J. Feuillard
Laboratoire d'Hématologie and Service d'Hématologie Clinique, CHU Dupuytren, Limoges, France

C008
Clinical and molecular features in patients with juvenile myelomonocytic leukemia-like myeloproliferative disease and Noonan syndrome.
C.P. Kratz, C.M. Niemeyer on behalf of the European Working Group on Childhood MDS (EWOG-MDS)
Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany

16:00-18:00 Simultaneous Oral Sessions

SESSION II: Diagnosis and Prognosis

Chairmen: G. Castoldi, G. Mufti

C009
Identification of dysplastic features in patients with myelodysplastic syndromes by multiparameter flow cytometry and correlation with cytomorphology and cytogenetics.
C010
Commercially available array-CGH BAC platforms: Pitfalls in interpreting results.
G. Barba, C. Matteucci, L. Brandimarte, R. La Starza, V. Pierini, C. Mecucci
Hematology, University of Perugia, IBiT Foundation, Fondazione IRCS Biotecnologie nel Trapianto, Perugia, Italy

C011
Marked telomere loss following autologous stem cell transplantation may be predictive for the onset of secondary myelodysplastic syndrome/acute leukemia.
Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale - Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy

C012
Prevalence and prognostic significance of allelic imbalance by single nucleotide polymorphism analysis in low risk myelodysplastic syndromes.
King's College London School of Medicine, London, UK; Heinrich-Heine-University, Düsseldorf, Germany; St. Johannes Hospital, Duisberg, Germany; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

C013
The influence of therapeutic strategies on survival in distinct cytogenetic subgroups- A collaborative study based on 3860 patients with MDS.
the German-Austrian MDS study group and the MD Anderson Cancer Centre, Houston, Texas, USA

C014
Influence of different treatment strategies on the prognosis of patients with myelodysplastic syndromes (MDS).
Department of Hematology, Heinrich-Heine-University Düsseldorf, Germany
C015
Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS).
Department of Hematology, Heinrich-Heine-University Düsseldorf, Germany

C016
A previous diagnosis of myelodysplastic syndrome has no influence on the clinical outcome of elderly patients with acute myeloid leukaemia.
Division of Hematology and Stem Cell Unit, Cardarelli Hospital, Napoli, Italy

PASSI PERDUTI

18:00-19:30 Poster Sessions with wine & cheese
(session supported by an unrestricted educational grant from MSD)

SESSION I: Epidemiology and Classification
Chairmen: A. Levis, C. Mecucci

P001
Incidence of myelodysplastic syndromes in the United States Medicare population.
S.L. Goldberg, MD, Cancer Center, Hackensack University Medical Center
N. Mody-Patel, PharmD, Novartis Pharmaceuticals, Florham Park, NJ
N. Warnock, MD, Quorum Consulting, San Francisco, CA, USA

P002
Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS register.
On behalf of the Piedmont MDS Registry, Alessandria, Italy.
P003
Data from the registry of the patients with myelodysplastic syndrome from Clinic of Hematology, Fundeni Clinical Institute, Bucharest, Romania. I. Epidemiological general data.
R. Gologan, D. Georgescu
Clinic of Hematology, Fundeni Clinical Institute, Bucharest, Romania

P004
Clinico-hematologic and prognostic features of myelodysplastic syndromes of children in Belarus.
N. Klimkovich
Faculty of children’s oncology and hematology, Byelorussian National Advanced Doctor2s Training Academy, Pediatric Oncology and Haematology Center, Minsk, Belarus

P005
MDS incidence and mortality in UK General Practice Research Database.
J.P. Fryzek, C.M. Kuehn, Amgen, Inc; J.A. Kaye
Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, USA

P006
Idiopathic cytopenia of uncertain significance (ICUS) versus low risk MDS: the diagnostic interface.
P. Valent, F. Wimazal, C. Fonatsch, R. Thalhammer; I. Schwarzinger; L. Müllauer; W.R. Sperr; J.M. Bennett
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Department of Human Genetics, Clinical Institute of Medical and Chemical Laboratory Diagnostics, & Institute of Clinical Pathology, all at the Medical University of Vienna; and James P.Wilmot Cancer Center, and University of Rochester Medical Center, Rochester, NY, USA

P007
Both HLA DRB1*11 and DRB1*15 are observed more frequently among patients with myelodysplastic syndrome compared to healthy controls.
S.M. Bakanay, K. Dalva, T. Cevirgen, A.U. Bilgin, M. Beksac
Ankara University Medical School, Department of Hematology and Stem Cell Transplantation Unit, Turkey

P008
AML1/RUNX1 point mutations are frequent in MDS/AML among the residents of Semipalatinsk near former USSR nuclear test site.
A. Kimura, N. Chaizhunussova, Z. Dinara, H. Harada; Y. Harada
Department of Hematology and Oncology, Radiation Biophysics, International Radiation Information Center, Hiroshima University, Kazakh Scientific Research Institute for Radiation Medicine and Ecology
P009
Genetic polymorphisms of DNA-repair- and detoxification enzymes in therapy-related AML and MDS.
S. Fischer, C. Seedhouse, T. Schulz, G. Westphal, D. Haase
Dept. of Hematology and Oncology, University of Göttingen, Germany; Academic Hematology, Nottingham City Hospital, UK; Inst. of Occupational Medicine, University of Göttingen, Germany

P010
Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: A GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients.
Division of Hematology, Tumor Epidemiology and Nuclear Medicine-University of Torino; Division of Medical Oncology and Hematology, Istituto Nazionale Tumori, University of Milano; Division of Hematology-University of Verona; Division of Hematology, Cervello Hospital, Palermo; Division of Hematology, S. Raffaele Hospital, Milano; Division of Hematology, S. Croce Hospital, Cuneo; Division of Hematology, S. Maurizio Hospital, Bolzano; Division of Hematology, S. Camillo Hospital, Roma; Division of Hematology, Ospedali Riuniti, Bergamo, Italy

P011
Clinical features and prognosis of patients with refractory cytopenia with multilineage dysplasia: results of multi-center analysis in Korea.
Yonsei University College of Medicine, Seoul, Chonnam National University Hwasun Hospital, Chonnam, Seoul National University, College of Medicine, Seoul, Sungkyunkwan University School of Medicine, Seoul, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Kyung Hee University School of Medicine, Seoul, Soonchunhyang University Hospital, Gyeonggi-Do, College of Medicine, Chungnam National University, Daejeon, Hallym University Medical Center, Gyeonggi, Korea

P012
Clinical features and prognosis of patient with chromosome 5 abnormalities: results of multi-center analysis in Korea.
P013  
Chronic myelomonocytic leukemia: one disease with two phases or two different diseases?  
A. Symeonidis, N. Giannakoulas, A. Kouraklis-Symeonidis, E. Michali, V. Lambropoulou, N. Anagnostopoulos, N. Zoumbos  
Hematology Division, Dept of Int. Medicine, University of Patras Medical School, Patras, "G. Gennimatas" Hospital, Athens, Greece

P014  
Chromosomal pattern study in hypocellular primary myelodysplastic syndrome and its correlation with clinical and cellular aspects.  
Bone Marrow Unit, National Cancer Institute, Rio de Janeiro, Brazil, Department of Pathology and Hematology, Medicine School, Rio de Janeiro State University - Rio de Janeiro, Brazil; Hematology Department - National Cancer Institute - Rio de Janeiro, Brazil; Hematology Institute Rio de Janeiro, Brazil

P015  
Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorised as unclassified (MDS/MPD-ú) by who classification.  
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy; Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy

P016  
Features of secondary myelodysplastic syndrom in persons suffered from Chernobyl accident.  
I. Dyagil, V. Bebeshko, T. Lubarets, V. Sholoiko, I. Byelinska, Z. Misharina  
Research Center for Radiation Medicine, Kiev, Ukraine
P017
Transient leukemia in Down Syndrome newborns.
Dipartimento di Scienze Pediatriche - Università di Torino - e Dipartimento di Patologia Clinica, Ospedale Regina Margherita, Torino, Italy

18:00-19:30 Poster Sessions
with wine & cheese
(session supported by an unrestricted educational grant from MSD)

SESSION II: Molecular Mechanisms and Pathophysiology I - Stromal Cells, Cytokines and Apoptosis
Chairmen: G. Torelli, A. Zanella

P018
Correlation between Microvessel Density (MVD) and Vascular Endothelial Growth Factor (VEGF) expression in myelodysplastic syndromes (MDS).
UO1 Hematology-BMT Unit, UO2 Hematology, Fondazione Ospedale Maggiore Policlinico IRCCS, Department of Medicine, Surgery and Dental Sciences, II Pathology Unit, A.O. S.Paolo, Università degli Studi di Milano, Milan, Italy

P019
TNF-alpha" and VEGF serum levels in patients with different subtypes of MDS.
N. Serafyn, J. Vyhovska, O. Danysh, N. Tomashevsk, Z. Masliah
Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine

P020
Functional characterization of adult mesenchymal stromal cells from patients with myelodysplastic syndrome.
S. Boxberger, M. Bornhäuser, B. Mohr, M. von Bonin, G. Ehniger, U. Platzbecker
Med. Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
P021
Citogenetic characterization by array comparative genomic hybridization and fluorescence in situ
hybridization of mesenchymal stem cells from patients with myelodysplastic syndromes.
Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain

P022
Impaired clonogenic and proliferative potential of bone marrow mesenchymal stem cells in patients with
myelodysplastic syndromes.
E. Stavroulaki, M. Klaus, M-C. Kastrinaki, C. Kalpadaki, G. Gvazava, M. Ximeri, M. Psyllaki, A. Galanopoulos, A-N. Viniou, A.
Haemopoiesis Research Laboratory of the University of Crete School of Medicine, Heraklion, Crete, Greece

P023
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukemias and
myelodysplastic syndromes.
R. Invernizzi, E. Travaglino, C. Benatti, B.K. Guglielmana, L. Malcovati, M.G. Della Porta
Internal Medicine and Medical Oncology, Institute of Hematology, University of Pavia, Fondazione IRCCS Policlinico S.
Matteo, Pavia, Italy

P024
PKC-zeta involvement in the impaired SDF1a-mediated migration of marrow CD34+ cells from MDS
patients.
E. Thanopoulou, L. Pherson, Th. Grigorakaki, O. Tsopra, E. Lagadinou, N. Zoumbos
Hematology Division, Patras University Medical School, Greece

P025
DAP-kinase hypermethylation and apoptosis in myelodysplastic syndromes.
Hohaus, G. Leone
Istituto di Ematologia, Universita’ Cattolica S. Cuore, Roma, Italy

P026
Different pattern of JNK activity in MDS-related versus de novo AML: Implications for apoptosis-
resistance and treatment failure in MDS-related AML.
E.D. Lagadinou, P. Ziros, O. Tsopra, A. Klamargias, E. Thanopoulou, A. Kourakis, A. Spyridonidis, M. Karakantza, N.C.
Zoumbos
Department of Internal Medicine, Hematology Division, University Hospital of Patras, 26500 Patras, Greece
P027
Analysis of cell cycle regulatory genes expression in the bone marrow of adult de novo myelodysplastic syndromes (MDS).
C. Economopoulou, V. Pappa, F. Kontsioti, V. Kapsimali, P. Tsirigotis, S. Papageorgiou, V. Giannopoulou, K. Girkas, E. Papageorgiou, J. Dervenoulas, T. Economopoulos
Second Department of Internal Medicine Propaedeutic, University of Athens, Attikon University General Hospital, Athens, Greece; Immunology Department, Evangelismos Hospital, Athens, Greece

P028
High levels of telomerase activity in myelodysplastic syndromes are associated with eroded telomeres and shorter survival.
Institute of Hematology and Blood Transfusion, Prague, Czech Republic, 1st Medical Faculty, Charles University, Prague, Czech Republic, Center of Oncocytogenetics, General Faculty Hospital, Prague, Czech Republic

P029
Early progenitor cells antigens and apoptosis in patients with secondary myelodysplasia exposed to ionizing radiation after Chernobyl accident.
I. Ilyenko, D. Bazyka, S. Klymenko, T. Lubarets, N. Golyarnik
Research Center for Radiation Medicine, Kiev, Ukraine

P030
A role for the endoplasmic reticulum in the apoptosis of erythroid precursors in low risk myelodysplastic syndromes.
Cochin Institute, University Paris Descartes, CNRS (UMR 8104), Inserm U567, France Department of Internal Medicine, University Hospital Purpan, Toulouse, Inserm U517, Faculty of Medicine, Dijon, University of Burgundy, IFR100, Faculty of Medicine, Dijon, France. Laboratory of Hematology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris

P031
Differentiation of early stage myelodysplastic syndrome-deriving erythroid precursors by ectopic expression of NACA.
L. Stuhl, V. Gelsi-Boyer, M. Conesa, V. Trouplin, D. Bimbaum, N. Vey, P. Dubreuil, S. Gomez
Centre de Recherche en Cancérologie de Marseille. INSERM UMR599, Institut Paoli-Calmettes, Université de la Méditerranée, Marseille, France
P032  
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.  
H. Ghoti, J. Amer, A. Winder, E. Rachmilewitz, E. Fibach  
Department of Hematology, The E. Wolfson Medical Center, Holon; Department of Hematology, Hebrew University - Hadassah Medical School, Jerusalem, Israel

P033  
The Akt/mTOR signal transduction pathway is activated in high risk myelodysplastic syndromes and influences cell survival and proliferation.  
Department of Anatomical Sciences, Cellular Signalling Laboratory, University of Bologna; Institute of Hematology “Seràgnoli”, University of Bologna; Italy

P034  
Urinary hepcidin excretion in patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF).  
A. Winder, R. Lefkowitz, H. Ghoti, M. Leiba, T. Ganz, E. Nemeth, E.A. Rachmilewitz  
Dept of Medicine and Pathology, David Geffen School of Medicine, Univ. of California, Los Angeles, CA, U.S.A; Dept of Hematology, BMT & CBB, Sheba Medical Center, Tel-Hashomer, Israel and Dept of Hematology, Wolfson Medical Center, Holon, Israel

P035  
Significance of bone marrow storage iron in patients with myelodysplastic syndromes.  
L. Wong, L. Go, W. Koss, T. Wajima  
Hematology/Oncology, Texas A&M University Health Science Center and Scott and White Clinic, USA

P036  
The oral iron chelator ICL670 is a potent inhibitor of NF-kB and this activity is independent from iron overload in MDS cells.  
D. Cilloni, V. Rosso, E. Messa, F. Messa, F. Arruga, I. Defilippi, R. Catalano, S. Carturan, C. Bittoto, C. Boveri, *P. Nicoli, E. Bracco, G. Saglio  
Dept. of Clinical and Biological Sciences, University of Turin, Turin, Italy

P037  
Treatment with Epo/G-CSF of patients with low/int-1 risk myelodysplastic syndrome diminishes relative CLIP (Class II-associated invariant chain peptide) amount on hematopoietic precursor cells.
P038
Inhibition of poly ADP ribose polymerase (PARP) induces cell death in leukaemic cell lines alone or synergistically with histone deacetylase inhibitors: potential for anti-leukaemia therapy.
T.J. Gaymes, S. Shall, F. Farzaneh, G.J. Mufti
Dept. of Haematological Medicine, Leukaemia Sciences Labs, The Rayne Institute, GKT School of Medicine, Denmark Hill campus, London SE5 9NU, UK

P039
The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML.
S. Boehrer, L. Adès, T. Braun, L. Galluzzi, J. Grosjean, C. Fabre, S. de Botton, C. Gardin, P. Fenaux, G. Kroemer
CNRS, FRE 2939, Institut Gustave Roussy; Hôpital Avicenne, AP-HP, Université Paris XIII; Institut Gustave Roussy, France

P040
Hypomethylation and apoptosis in 5-azacytidine treated myeloid cells.
Department of Medicine, Division of Hematology, Karolinska University Hospital - Huddinge, Karolinska Institute, SE-141 86 Stockholm; Institute of Environmental Medicine, Division of Toxicology, Departments of Molecular Medicine and Surgery, and Clinical Neuroscience, Karolinska University Hospital; Karolinska Institute, SE-171 76 Stockholm, Sweden
P041  
Monocyte and dendritic cell abnormalities in bone marrow of patients with myelodysplastic syndromes.  
Faculty of Medicine, State University of Campinas, Brazil

P042  
Alteration in immune effector cells in bone marrow of Myelodysplastic Syndrome Patients.  
Haematology div., Dep. Biochemical and Medical Biotechnology, University of Napoli “Federico II; Dep. Cell. And Mol. Biology and Pathology, University of Napoli “Federico II, Napoli, Italy

P043  
Activated monocytes contribute to bone marrow failure in myelodysplastic syndromes.  
S. Meers, A. Kasran, L. Boon, M. Boogaerts, P. Vandenberghe, G. Verhoef, C. Verfaillie, M. Delforge  
Hematology University Hospital Leuven, Belgium; Immunology, University of Leuven, Belgium; PanGenetics NV, Utrecht, The Netherlands; Stem Cell Institute Leuven, Belgium; SM is fellow and MD clinical professor of the Research Foundation-Flanders (FWO-Vlaanderen)

P044  
Increased expression of Toll-like Receptor 4 and 9 in the bone marrow of patients with Myelodysplastic Syndromes.  
Haemopoiesis Research Laboratory of the Department of Haematology, University of Crete, Greece

P045  
T-cell receptor repertoire in patients with myelodysplastic syndromes (MDS) receiving lenalidomide treatment.  
T. Momot, J. Koenig, A. Ganser, E-M. Weissinger  
MHH, Department of Hematology, Hemostasis and Oncology, Hannover, Germany

P046  
Characterization of the T-cell receptor repertoire in patients with myelodysplastic syndromes.  
T. Momot, J. Koenig, A. Ganser, E-M. Weissinger  
MHH, Department of Hematology, Hemostasis and Oncology, Hannover, Germany
P047
T-cell receptor (TCR) Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC).
Department of Pediatric Oncology/Hematology, Erasmus University Medical Center Sophia Children’s Hospital, Rotterdam, The Netherlands, Dutch Childhood Oncology Group, The Hague, The Netherlands, Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands, Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany, Department of Pediatric Hematology and Oncology, University Hospital, Motol, Prague, Czech Republic, National University Hospital, Copenhagen, Denmark

P048
Increased apoptosis of circulating T cells in myelodysplastic syndromes.
C. Satoh, Y. Shioi, H. Tamura, N. Yokose, K. Dan, K. Ogata
Division of Hematology and Division of Bioregulation, Department of Medicine, Nippon Medical School, Tokyo, Japan

P049
Impaired T cell function and reduced peripheral tolerance mechanisms in myelodysplastic syndrome (MDS).
Immunology Program, H. Lee Moffitt Cancer Center/University of South Florida, Tampa, FL; Hematologic Malignancy Division, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Research, Veterans Administration Hospital, Tampa, FL, USA

P050
Evidence for a role of CD4+CD25high Foxp3+ regulatory T-cells in the pathogenesis of Myelodysplastic Syndromes (MDS).
Department of Laboratory Haematology and Flow Cytometry, Dept of Haematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece

P051
Polyclonal CD4+CD25high Foxp3+ regulatory T-cells are significantly increased in high risk Myelodysplastic Syndromes (MDS).
Department of Hematological Medicine, King’s College London, UK; Immunoregulation Laboratory, Department of Nephrology and Transplantation, King’s College London, UK; Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Foundation, Cleveland, USA
P052
Detection of humoral immune responses against Wilms tumor gene (WT1) product in patients affected by myelodysplastic syndromes.
D. Cilloni, P. Nicoli, I. Defilippi, E. Girola, A. Bondi, E. Messa, A. Roetto, F. Messa, F. Arruga, S. Carturan, V. Rosso, R. Catalano, E. Bracco, G. Saglio
Dep. of Clinical and Biological Sciences, University of Turin, Turin, Italy

P053
High cytotoxic potential of CD8+/granzymeB+/perforin+ T cells prevents leukemic outgrow of dysplastic hematopoietic precursor cells in patients with low/int-I risk myelodysplastic syndrome.
M.E.D. Chamuleau, T.M. Westers, J. Groenland, A. Zevenbergen, L. van Dreunen, G.J. Ossenkoppele, A.A. van de Loosdrecht
VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands

P054
Anti-erythroblast autoimmunity in early MDS.
A. Zaninoni, F.G. Imperiali, M. Colombi, W. Barcellini.
Department of Hematology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy

P055
The decrease of B lymphocytes in MDS - what is the significance of it?
N. Radana, K. Josef
1st Med. Dept., Central Hematol. Lab., Charles Univ. Hospital, Prague, Czech Republic

P056
Is the increased apoptosis a cause of impaired CD34+ B-cell precursors production in myelodysplastic syndromes?
Division of Hematology and Transfusion Medicine, Universidade Federal de São Paulo - UNIFESP, Brazil
PASSI PERDUTI

18:00-19:30  **Poster Sessions** with wine & cheese
(session supported by an unrestricted educational grant from MSD)

**SESSION IV: Molecular Mechanisms and Pathophysiology III - Cytogenetics and Molecular Genetics**
Chairmen: M. Gobbi, F. Lauria

**P057**
Abrogation of the DNA-damage response in AML versus MDS cell lines.
S. Boehrer, L. Adès, T. Braun, J. Grosjean, C. Fabre, P. Fenaux, G. Kroemer
CNRS, FRE 2939, Institut Gustave Roussy, Villejuif, France; Hôpital Avicenne, AP-HP, Université Paris XIII, France

**P058**
Polymorphisms of glutathione S-transferase T1 and M1 in Greek patients with myelodysplastic syndrome in relation to patient characteristics and cytogenetic subgroups.
C. Stavropoulou, H. Riganas, V.N. Georgakakos, K.N. Manola, C. Sambani
Laboratory of Cytogenetics, NCSR “Demokritos”, 15310 Aghia Paraskevi, Athens, Greece

**P059**
DNA instability in low-risk myelodysplastic syndromes - refractory anemia with or without ring sideroblasts.
B. Novotna, V. Blázková, R. Něuwirtová, M. Sisková, Y. Bagryantseva
Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague; 1st Medical Clinic-hematologyoncology, General University Hospital, Prague 2, Czech Republic

**P060**
Effect of azacitidine on PI-PLC-beta1 expression and Akt activation in a patient affected by high-risk myelodysplastic syndrome (MDS).
Institute of Hematology “Seràgnoli”, University of Bologna; Department of Anatomical Sciences, Cellular Signalling Laboratory, University of Bologna, Italy
P061
Methylation status of the p15INKb and p16INKa genes in pediatric primary myelodysplastic syndrome.
Bone Marrow Unit, National Cancer Institute, Rio de Janeiro, Brazil; Human Genetic Department, Rio de Janeiro State University, Rio de Janeiro, Brazil; Martagão Gesteira Pediatric Institute, Rio de Janeiro, Brazil; Department of Pathology and Hematology, Medicine School, Rio de Janeiro State University, Rio de Janeiro, Brazil

P062
An increase in aberrant p15INKb gene methylation in myelodysplastic syndromes correlates with the number of bone marrow blasts and with the progression of the disease.
Institute of Hematology and Blood Transfusion, Prague, Czech Republic; 1st Medical Faculty, Charles University, Prague, Czech Republic; Center of Oncocytogenetics, General Faculty Hospital, Prague, Czech Republic

P063
Detection of methylation status changes in refractory anemia with ringed sideroblasts (RARS) by MS-MLPA.
Hematology Service, Hospital Universitario La Fe, Valencia, Spain; Genetic Unit, Hospital Universitario La Fe, Valencia, Spain

P064
Downregulation of microsomal carnitine palmitoyltransferase (mCPT) in myelodysplastic syndromes (MDS) induced by hypermethylation and/or reduced carnitine availability.
M. Pfeilstöcker, H. Karlic, P. Wihlidal, T. Nösslinger, E. Pittermann
Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria; 3rd Medical Department Hanusch Hospital, Vienna, Austria

P065
Coamplification at 8q24 and 11q23 in AML/MDS cell lines.
R. A. F. MacLeod, B. Schneider, S. Nagel, M. Kaufmann, H. G. Drexler
DSMZ, German Collection of Microorganisms and Cell Cultures, Department of Cell Cultures, Braunschweig, Germany

P066
WT1 expression in patients with myelodysplastic syndromes.
P067
Prion-like doppel gene (PRND) aberrant expression in acute myeloid leukemias and myelodysplastic syndromes.
R. Invernizzi, E. Travaglino, C. Benatti, A. Azzalin, B. Rovati, B.K. Guglielmana, S. Comincini
Clinica Medica 3, Dipartimento di Genetica e Microbiologia, Laboratorio di Citofluorimetria e Terapie Cellulari, Università di Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy

P068
Deletion of the ETV6/TEL gene in association with disruption of the MLL gene in a case of therapy-related myelodysplastic syndrome.
A. Lazaridou, S. Mayroudi, A. Nikitidou, K. Zerbas
Hematology Department, Cancer Hospital, Thessaloniki, Greece

P069
Genome-wide DNA-mapping of CD34+ cells from MDS patients with 500K SNP arrays identifies significant regions of genomic alterations.
D. Nowak, F. Wagner, F. Nolte, C.C. Baldus, O. Hopfer, M. Mossner, V. Serbent, E. Thiel, W.K. Hofmann
Department of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany and RZPD, Berlin, Germany

P070
Whole genome association study in leukemia: Frequent loss of heterozygosity in acute myeloid leukemia with a normal karyotype.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; Department of Internal Medicine, Seoul National University Bundang Hospital, Bundang, Gyeonggi-do, South Korea; Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Internal Medicine and Pathology, Hanyang University College of Medicine, Seoul, Korea; Corresponding author at: Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongundong, Chongro-gu, Seoul 110-744, South Korea

P071
Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes.
P072
Genomic profiling of CD34+ and CD61+ cells in 5q- Syndrome.
N.C. Lea, A. Mohamedali, N. Twine, J. Gaken, N. Westwood, W. Ingram, G. Mufti
Haemotological Medicine, Kings College Hospital, London, United Kingdom; Haematological Medicine, Kings College London, London, United Kingdom
Authors contributed equally

P073
Gene expression profiling in the myelodysplastic syndrome: patients with intermediate 1 versus higher risk.
A. Kracmarova, H. Bruchova, M. Belickova, J. van Delft, J. Cermak, R. Brdicka

P074
Molecular cytogenetic delineation of del(4q) in myelodysplastic syndromes with peripheral blood monocytosis.
R. La Starza, M. Cei, B. Crescenzi, C. Matteucci, L. Brandimarte, G. Barba, P. Gorello, M.F. Martelli, C. Mecucci
Hematology, University of Perugia, IBiT Foundation, Fondazione IRCCS Biotecnologie nel Trapianto, Perugia, Italy; Department of Internal Medicine, Livorno Hospital, Livorno, Italy

P075
JAK2 and MPL515 mutation analysis in RARS with PLT count >500.000/µL and in RARS-T according to WHO (PLT count >600.000/µL).
E. Zipperer, M. Wulfert, U. Germing, Gattermann N.
Department of Hematology/Oncology, Heinrich-Heine-University, Düsseldorf, Germany

P076
Acquisition of RAS and JAK2 mutations contributes to progression of CMML from the dysplastic to the proliferative variant.
Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Università di Milano; Fondazione Matarrelli per lo studio delle malattie del sangue, Milano; Istituto Nazionale Tumori IRCCS, Milano; Ospedale di Circolo, Rho, Milano, Italy
P077
C-FMS mutational analysis in chronic myelomonocytic leukemia (CMML).
Hematology Service, Hospital Universitario La Fe, Valencia, Spain

P078
No evidence for mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.
Department of Pediatric Oncology/Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; Erasmus MC, Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Germany; Dutch Childhood Oncology Group, The Hague, The Netherlands; Children's Cancer Research Institute, St. Anna Kinderspital, Vienna, Austria

P079
BRAF mutations in juvenile myelomonocytic leukemia.
Department of Pediatric Oncology/Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Germany; Institute of Human Genetics, University of Erlangen-Nuremberg, Germany; Children's Cancer Research Institute, Vienna, Austria; Dutch Childhood Oncology Group, The Hague, The Netherlands; Pediatric Hematology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark; Department of Pediatric Hematology and Oncology, Charles University, 2nd Medical School, Prague, Czech-Republic
Friday, May 18, 2007

AUDITORIUM

8:30-10:00 Clonal Proliferation and Clonal Dominance in Myeloid Disorders
Chairwoman: C. Mecucci

8:30-9:00 Paroxysmal nocturnal hemoglobinuria
R. Notaro

9:00-9:30 Genetics of chronic myeloproliferative disorders
R. Skoda

9:30-10:00 Acute myeloid leukemia carrying cytoplasmic mutated nucleophosmin (NPMc+ AML): molecular and clinico-pathological features
B. Falini

EXHIBITION AREA

10:00-10:30 Coffee break

AUDITORIUM

10:30-12:00 Novel Diagnostic and Prognostic Tools
Chairman: A.A. Giagounidis
10:30-11:00 Flow cytometry immunophenotyping  
M.G. Della Porta

11:00-11:30 Molecular markers  
J. Wainscoat

11:30-12:00 WPSS, a dynamic prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes  
L. Malcovati

12:00-13:30 Symposium on Iron Overload and Survival of Patients with Myelodysplastic Syndrome (sponsored by Novartis)
Chairman: M. Cazzola

12:00-12:20 Impact of transfusion dependency and secondary iron overload of the survival of patients with myelodysplastic syndrome  
L. Malcovati

12:20-12:40 Improved survival in MDS patients receiving iron chelation therapy  
H.A. Leitch

12:40-13:00 Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload  
N. Gattermann

13:00-13:20 Deferasirox - the novel, once a day oral iron chelator  
S. L. Goldberg

13:20-13:30 Panel discussion/debate
FRIDAY, MAY 18, 2007

PALAFFARI Ground and 1st Floor

13:30-14:30  Open Time for Lunch

AUDITORIUM

14:30-15:30  Ineffective Hematopoiesis and the Use of Hematopoietic Growth Factors in Myelodysplastic Syndromes (session supported by an unrestricted educational grant from Roche)
Chairman: A. Ganser

14:30-15:00  Increased apoptosis as a mechanism of ineffective hematopoiesis in myelodysplastic syndromes
R. Invernizzi

15:00-15:30  Treatment of myelodysplastic syndromes with erythropoietin and G-CSF
E. Hellström-Lindberg

AUDITORIUM

15:30-16:00  The Growing Importance of Hematopoietic Growth Factors in Myelodysplastic Syndromes (session supported by an unrestricted educational grant from Amgen)
Chairman: P. Greenberg
15:30-16:00 Hematopoietic growth factors in the treatment of neutropenia and thrombocytopenia of myelodysplastic syndromes
D.T. Bowen

16:00-18:00 Simultaneous Oral Sessions

**PALAFFARI 2nd Floor**

**SESSION III: Molecular Mechanisms and Pathophysiology**

Chairwomen: C. del Cañizo, E. Hellström-Lindberg

C017 Animal model of mitochondrial dysfunction generating macrocytic anemia and myelodysplastic bone marrow failure.
J.E. Thompson, S.G. Shelat, G. Kujoth, V.P. Zediak, A. Bhandoola, T. Prolla
Departments of Medicine and Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; Departments of Genetics and Medical Genetics, University of Wisconsin, Madison, WI, USA

C018 Del (20q), a benign clonal abnormality, involves totipotent stem cells in Shwachman Diamond Syndrome.
B. Crescenzi, R. La Starza, C. Sambani, A. Parcharidou, L. Brandimarte, C. Matteucci, M.F. Martelli, C. Mecucci
Hematology, University of Perugia, IBiT Foundation, Fondazione IRCS Biotecnologie nel Trapianto, Perugia, Italy

C019 Genome-wide analysis of copy number change and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density SNP arrays.
L. Wang, C. Fidler, A. Giagounidis, M. Cazzola, L. Malcovati, S. Killick, C. Aul, J. Boultonwood, J.S. Wainscoat
LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK, Medizinische Klinik II, St Johnnes Hospital, Duisburg, Germany, Division of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Pavia, Italy, Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK
C020
Identification of novel genetic lesions in MDS using high density SNP-arrays.
S. Langemeijer, R. Kuiper, B.A. vd Reijden, T. de Witte, J.H. Jansen
Central Hematology Laboratory and Dept Hematology, Nijmegen Centre for Molecular Life Sciences, Radboud University MC Nijmegen, The Netherlands

C021
SNP-array karyotyping complements routine metaphase cytogenetics in the detection of chromosomal aberrations including uniparental disomy in MDS.
Experimental Hematology and Hematopoiesis, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Graduate School of Medicine, University of Tokyo, Japan

C022
NPM1 monoallelic deletion in a subgroup of MDS/AML with del(5q) or monosomy 5 and complex karyotype.
Hematology, University of Perugia, IBiT Foundation, Fondazione IRCCS Biotecnologie del Trapianto, Perugia, Servei de Hematologia, Hospital De La Santa Creu i Sant Pau, Barcelona, Spain; Dpt Hematology, University “La Sapienza”, Rome, Italy; Internal and Vascular Medicine, University of Perugia, Italy

C023
Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes.
LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK; Division of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Pavia, Italy; Medizinische Klinik II, St Johannes Hospital, Duisburg, Germany; Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden; Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK; Department of Haematology, Leeds General Infirmary, Leeds, UK

C024
Impaired mitochondrial gene expression in MDS patients.
V. Schildgen, B. Junge, N. Gattermann
Department of Hematology/Oncology, Heinrich-Heine-University, Düsseldorf, Germany
16:00-18:00 Simultaneous Oral Sessions

AUDITORIUM

SESSION IV: Treatment

Chairmen: R. Foà, N.C. Zoumbos

C025
Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to anti-thymocyte globulin.
Department of Haematological Medicine, Kings College London and Kings College Hospital, United Kingdom; Department of Haematology, Royal Bournemouth NHS Foundation Trust, United Kingdom; Dept of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany;Department of Haematology, St Batholomew’s and The Royal London Hospitals, United Kingdom; Department of Haematology, Aberdeen Royal Infirmary, United Kingdom; Dipartimento di Emato-Oncologia, Ospedale San Martino, Genova, Italy; Department of Haematology, St George’s Hospital, United Kingdom

C026
Childhood refractory cytopenia: Clinical, hematological features and response to immunosuppression.
Department of Pediatrics, University of Freiburg, Germany; Department of Pathology, Bayreuth Hospital, Germany; Division of Pediatric Hematology and Oncology, University Children’s Hospital Zurich, Switzerland; Azienda Ospedaliera San Giovanni-Addolorata UOD Ematologica, Rome, Italy; Oncoematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy; Department of Pediatrics, Skejby Hospital, Aarhus University, Denmark; Institute of Pathology, Odense University Hospital, Odense, Denmark, Dutch Childhood Oncology Group, the Hague, ErasmusMC-Sophia Children’s Hospital, Rotterdam, The Netherlands; Department of Pediatric Hematology/Oncology, Charles University, University Hospital Motol, Prague, Czech Republic; Department of Pediatrics, St Anna Children’s Hospital, Vienna, Austria; Dutch Childhood Leukemia Study Group, The Hague, The Netherlands
C027
Cytopenias correlate with response to lenalidomide in del 5q MDS patients.
M.A. Sekeres, J.P. Maciejewski, A. Giagounidis, K. Wride, R. Knight, A. List
Cleveland Clinic Taussig Cancer Cntr; St Johannes Hosp; Celgene Corp; H Lee Moffitt Cancer Cntr; USA

C028
Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion.
A.F. List, K. Wride, G.W. Dewald, J.M. Bennett, A. Giagounidis, S. Kurtin, R.D. Knight
H. Lee Moffitt Cancer Center, Tampa, FL; Celgene, Summit, NJ; Mayo Clinic, Rochester, MN; U. Rochester, Rochester, NY;
St. Johannes Hospital, Duisburg, Germany; Arizona Cancer Center, Tucson, AZ, USA

C029
Hematopoietic stem cell transplantation for advanced primary MDS in children: results of a retrospective analysis from the EWOG-MDS group.

C030
Hematopoietic stem cell transplantation after a myeloablative conditioning regimen in children with refractory cytopenia: results of a retrospective analysis from the EWOG-MDS group.

C031
Allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndromes 50 years or older: A retrospective survey from the European group for Blood and Marrow Transplantation.
On behalf of the MDS subcommittee of the Chronic Leukemia Working Party of the European group for Blood and Marrow Transplantation

C032
Allogeneic hemopoietic stem cell transplantation for patients with myelodysplastic syndrome: the effect of blast count and disease status at transplant.
Divisione di Ematologia e Trapianto di Midollo , Ospedale San Martino, Genova, Italy
**PASSI PERDUTI**

**18:00-19:30 Poster Sessions** with wine & cheese  
(session supported by an unrestricted educational grant from MSD)

**SESSION V: Diagnostic and Prognostic Tools I**

**Morphology and New Diagnostic Tools**

Chairmen: C. Castagnola, P. Leoni

**P080**  
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome.  
C. Benatti, E. Travaglino, E. Ascari, B.K. Guglielmana, L. Malcovati, M.G. Della Porta, R. Invernizzi  
Internal Medicine and Medical Oncology and Institute of Hematology, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

**P081**  
Assessment of myelodysplasia in MDS and secondary leukemia. Application of a scoring table to the WHO classification.  
V. Andrieu, E. Duchayne, M. J. Grange, M. Guesnu, M. Imbert, F. Picard and the Groupe Français des Myélodysplasies Laboratoire d’Hématologie  
CHU Bichat-C Bernard, Paris, Laboratoire d’Hématologie, CHU Purpan, Toulouse, Laboratoire d’Hématologie, CHU Cochin, Paris, Laboratoire d’Hématologie, CHU H Mondor, Créteil, France

**P082**  
Primary myelodysplastic syndromes (MDS) with less than 5% of blasts in bone marrow: study of 147 patients from two centers in São Paulo, Brazil.  
Hematology Service of Hospital das Clinicas São Paulo Medical School, Hematology Department of Universidade Federal de São Paulo, Brasil

**P083**  
Clinical, hematological, cytogenetic and immunophenotypic profile in myelodysplastic syndrome patients in Rio de Janeiro, Brazil.
Department of Pathology and Hematology, Medical School, Rio de Janeiro State University, Rio de Janeiro, Brazil; Bone Marrow Unit, National Cancer Institute, Rio de Janeiro, Brazil

P084
Morphological diagnosis of low grade myelodysplastic syndrome in childhood.
I. Baumann, EWOG-MDS in Childhood
Institute of Pathology, Klinikum Bayreuth GmbH, Bayreuth, Germany

P085
Morphologic differential diagnosis of juvenile myelomonocytic leukemia (JMML).
A. Karow, C.M. Niemeyer on behalf of the European Working Group on Childhood MDS (EWOG-MDS)
Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany

P086
Flow cytometry in myelodysplastic syndromes: a new tool in the classification and prognostification of low/int-1 risk MDS.
Department of Haematology, VU University Medical Centre, Amsterdam, Netherlands and Department of Immunology, Erasmus University Medical Centre, Rotterdam, the Netherlands

P087
Use of multiparametric flow cytometry analysis (six-color) for the detection of Leukemia Associated ImmunoPhenotypes (LAIP) in myelodysplastic syndromes (MDS).
L. Campos, P. Flandrin, N. Nadal, J. Tinat, D. Guyotat
Laboratoire de Hematologie, Hopital Nord, and Institut Cancérologie de la Loire, Saint-Etienne, France

P088
Challenging diagnosis of refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS): detection of myeloid dysplasia by flow cytometry (FC).
Hematology Departments of: Clínica Quirón, Moncloa, and Rúber; Fundación Jiménez Díaz; Gemolab Laboratory, Madrid, Spain
P089
Biological significance of CD7-positive blasts in myelodysplastic syndromes.
Nippon Medical School and Tokyo University of Science, Japan

P090
B7.1 expression on blasts in myelodysplastic syndromes.
Nippon Medical School; Tokyo University of Science, Japan

P091
B7-H1 molecules on blasts in myelodysplastic syndromes.
Nippon Medical School; Tokyo University of Science, Japan

P092
Granulocytes Subpopulations Phenotypic Pattern Of MDS.
M. Vikentiou, K. Psarra, V. Kapsimali, K. Liapis, K. Tsionos, E. Lianidou, C. Papasteriades
National University of Athens, Evangelismos Hospital, 251 General Hospital, Athens, Greece

P093
Changes in the flow cytometric dysplasia score during treatment with erythropoietin/G-CSF reflect responses in low/int-I risk myelodysplastic syndromes.
Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands

P094
Erythroleukemia might be a possible erythroblastic transformation from myelodysplastic syndrome: Molecular cytogenetic study on the clonality of erythroid lineage by immunomagnetic bead and immunophenotyping.
Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul
P095
Chromosome 5q deletion in myelodysplastic syndrome.
Medical University of Warsaw, Medical University of Lodz, Medical University of Gdansk, Jagiellonski University, Kraków, Institute of Hematology and Transfusiology, Silesian Medical University, Medical University of Białystok, Medical University of Wroclaw, Specialistic Hospital in Toruk, Poland

P096
AML/MDS with chromosome 5 and 7 abnormalities.
A. Stamatoullas, A. Gouin, C. Bastard, M.P. Callat, H. Tilly
Département d’Hematologie, Centre Henri Becquerel; Département de biologie moleculaire Oncologique Centre Henri, Becquerel, Laboratoire d’Hematologie, CHU, Rouen, France

P097
Detection of complex chromosome abnormalities in patients with myelodysplastic syndrome. - involvement of chromosome 5.
A. Lazaridou, S. Mavroudi, A. Nikitidou, K. Zervas
Hematology and Cytogenetics department, Cancer Hospital of Thessaloniki, Greece

P098
Diagnostic and prognostic significance of tryptase in clinical hematology: evaluation of 1041 patients.
W.R. Sperr; A. El-Samahi, M. Girschikofsky, S. Winkler; H. Semper; H. Agis, C. Sillaber; G. Endler; H. Rumpold, D. Lutz, P. Valent
Dept of Int Med I, Div of Hematol and Div of Infect Diseases, Inst of Chem Lab Diag, Med Univ of Vienna, KH der Elisabethinen Linz, Dept of Int Med I, Austria

P099
Comparison of IWG 2006 and IWG 2000 response criteria for anemia of MDS in 419 patients: the GFM experience.
18:00-19:30 Poster Sessions with wine & cheese
(session supported by an unrestricted educational grant from MSD)

SESSION VI: Diagnostic and Prognostic Tools II
Prognostic Factors and Scoring Systems
Chairmen: E. Brusamolino, A. Grossi

P100
Retrospective WHO re-classification of 650 MDS patients diagnosed by FAB criteria: prognostic relevance.
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy

P101
Thrombocytopenia in MDS: incidence and impact.
H. Kantarjian, F. Giles, A. List, R. Lyons, M. Sekeres, S. Pierce, R. Deuson, J. Leveque
MDACC, TX; H. Lee Moffitt Cancer Center and Research Institute, FL; Cancer Care Centers of South Texas/US Oncology, TX; Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Amgen, CA, USA

P102
Thrombocytopenia at diagnosis as an important independent negative prognostic marker for low risk MDS patients.
A.T. Jonasova, R. Neuwirtova, H. Krejcova
Haematology, I. Medical Department, General Faculty Hospital, Charles University, Prague, Czech Republic

P103
Prognostic significance of LDH as a dynamic variable in myelodysplastic syndromes.
W.R. Sperr, F. Wimazal, A. Vales, M. Kundi, A. Böhm, R. Thalhammer, I. Schwarzinger, P. Valent
Dept of Int Med I, Div of Hematol and Hemostaseol, Inst of Enviromental Hygiene, Clin Inst of Med and Chem Lab Diag, Medical Univ of Vienna, Austria

P104
Prognostic role of transfusion requirement in myelodisplastic syndromes.
PI05  
The number of red blood cell transfusions is a significant but not an independent factor affecting survival in early MDS patients.  
J. Cermak, P. Kacirkova, D. Mikulenkova, K. Michalova  
Institute of Hematology and Blood Transfusion, Praha, Czech Republic

PI06  
Is cytogenetic follow-up useful in patients with myelodysplastic syndrome? A study of 119 analyses in 79 patients.  
A.M. Pelizzari, M. Drera, D. Bellotti, D. Marocolo, S. Barlati, F. Facchetti, G. Rossi  
Divisione Ematologia, Spedali Civili, Brescia; Dipartimento di Scienze Biomediche e Biotecnologie, Sezione di Biologia e Genetica, Università degli Studi di Brescia; I Servizio di Anatomia Patologica Spedali Civili, Cattedra di Anatomia Patologica, Università degli Studi di Brescia; Brescia, Italy

PI07  
Sequential molecular cytogenetic analysis of circulating CD34+ cells in MDS, a suitable method to monitor and predict response to 5-Azacytidine.  
F. Braulke, J. Schanz, D. Haase  
Department of Hematology and Oncology, Georg August University, Goettingen, Germany

PI08  
The joint impact of cytogenetics, together with age, gender and classification on survival in MDS.  
A. Makrai, H. Tüchler, T. Nösslinger, E. Pittermann, M. Pfeilstöcker  
Hanusch-Hospital Vienna, Ludwig Boltzmann Inst, Austria (Hematology and Leukemia Research)

PI09  
Revised ipss cytogenetic categories and who classification allow a better prognostic definition of patients with de novo myelodysplastic syndromes.  
P. Bernasconi, C. Klersy, M. Boni, P.M. Cavigliano, S. Calatroni, I. Giardini, B. Rocca, R. Zappatore, M. Caresana, I. Dambruoso, M. Lazzarino, C. Bernasconi  
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia; Scientific Direction, Clinical Epidemiology and Biometry Service, Fondazione IRCCS Policlinico San Matteo, Italy
P110
Individualized IPSS in MDS by considering age, gender and FAB-A multicenter analysis.
Hanusch-Hospital Vienna, Dusseldorf, AKH Vienna, Linz, Gottingen, Innsbruck, Austria

P111
Analysis of modified WHO classification-based Prognostic Scoring System (WPSS) for Japanese MDS patients.
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan,
Department of Hematology, Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate
School of Biomedical Sciences, Nagasaki, Japan

P112
Prognostic impact of bone marrow fibrosis in myelodysplastic syndromes (MDS).
S. Baghikar, S. Braunstein, P. Reinecke, S. Knipp, R. Haas, B. Hildebrandt, N. Gattermann, U. Germing, A. Schmidt-Graef
Heinrich-Heine-University Düsseldorf, University Freiburg, Germany

P113
Chronic myelomonocytic leukemia with monosomy 7 after successful treatment of acute promyelocytic leukemia.
J. Ramzi, G. Emna, B.N. Hend, M. Samia, A. Lania, K. Karima, B.A. Ramzi, B.L. Rainane, B.A. Hela, B. Zahe, M. Balkis
Department of hematology Aziza Othmana Hospital, Tunis; Institut de Pasteur, Tunis, Tunisia

P114
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 37 patients.
F. Demirkan, I. Alacacioglu, G.H. Ozsan, O. Piskin, M. Ali Ozcan, S. Bahceli, N. Turgut, B. Undar
Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, Turkey; Dokuz Eylul University Faculty of Medicine, Department of Internal Medicine, Izmir, Turkey

P115
Prognostic factors in chronic myelomonocytic leukaemia: a retrospective analysis of 113 patients.
A. Stamatoullas, A. Waultier, M.P. Callat, D. Penther, H. Tilly, C. Bastard
Département d'Hématologie, Centre Henri Becquerel; Laboratoire d'Hématologie, CHU; Département de biologie moléculaire Oncologique, Centre Henri Becquerel, Rouen, France
Comparison of MDS patients with long survival to short survival patients. Analysis of cases with discrepancy between low IPSS and survival.
R. Neuwitrova, H. Krejcová, A. Smolíkova, E. Polonyova, P. Kessler, A. Jonasova
Czech cooperative MDS group, 1st Med. Dept., Charles University Hospital, Prague

Prevalence of cardiac disease among a US Medicare population with myelodysplastic syndromes.
S.L. Goldberg, N. Mody-Patel, N.J. N.Warnock. Hackensack University Medical Center, PharmD, Novartis Pharmaceuticals, Florham Park, and Quorum Consulting, San Francisco, CA, USA.

Detection of cardiac iron by T2* MRI in transfusion dependent patients with acquired anemias.
S. Deplano, A. Di Tucci, M. Pettinau, E. Usala, E. Angelucci

The integration of comorbidity in decision making in myelodysplastic syndromes.
Division of Hematology and Oncology, Innsbruck Medical University, 3rd Med. Dept. for Hematology and Oncology, Hanusch Hospital and Ludwig-Boltzmann Institute for Leukemia Research and Hematology, Vienna; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna; First Department of Internal Medicine, Elisabethinen Hospital, Linz, Austria

The development of a frailty index for elderly patients with MDS.
B. Deschler, B. Rüter, R. Claus, Ihorst, M. Lübbert
Freiburg University, Medical Center, Germany

Coping with myelodysplastic syndromes (MDS): Lessons learned from those living with the disease.
M. Laudon Thomas, K. Heptinstall. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, and MDS Foundation, Crosswicks, New Jersey, USA.

Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients.
P123
Common troublesome symptoms and their impact on health-related quality of life (QOL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey.
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; The Myelodysplastic Syndromes
Foundation, Crosswicks, New Jersey; Cancer Center Statistics, Department of Biostatistics and Health Sciences Research,
Mayo Clinic, Rochester, Minnesota; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Scottsdale,
Arizona; Chronic Myeloproliferative Disorders Education Foundation, Scottsdale, Arizona, USA

P124
Quality of life (QoL) in myelodysplastic syndromes (MDS): an update of results from U.S. & European patient forums.
Kathleen Heptinstall, BSN, RN, for The MDS Foundation, Inc., Crosswicks, NJ, USA

P125
Pregnancy in patients with myelodysplastic syndromes.
Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza di Roma, Italy

PASSI PERDUTI

18:00-19:30 Poster Sessions with wine & cheese
(session supported by an unrestricted educational grant from MSD)

SESSION VII: Treatment I
Transfusion Therapy and Iron Chelation, Hematopoietic Growth Factors
Chairmen: M. Lazzarino, B. Rotoli
P126
Do elderly patient suffering from myelodysplastic syndromes (MDS) acced to investigational drugs? Study of a French cohort of 82 MDS in a population-based sample 80 years and older.
M.P. Chaury
Service d'Hematologie Clinique et Therapy cellulaire, Chu, Limoges, France

P127
Prospective cross-sectional analysis of cytopenias and transfusion needs of MDS patients in the United States.
M. Sekeres, H. Kantarjian, A. List, E. Lam, J. Leveque, R. Paquette, J. Maciejewski
Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, MD Anderson Cancer Center, Houston, Texas, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, Amgen, Inc., Thousand Oaks, California, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA

P128
Retrospective survey highlights the iron burden in Japanese transfusion-dependent patients with MDS.
Jichi Medical Univ; Kyoto Univ; Keio Univ; Osaka Univ; Akita Univ; Nagasaki Univ; Kanazawa Univ; Kyushu Univ; and Nagoya Univ, Japan

P129
Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670).
Heinrich-Heine-Univ, Düsseldorf, Germany; Univ Hosp Ulm, Ulm, Germany; on behalf of the French MDS Group (GFM); Policlinico S Matteo, Pavia, Italy; Policlinico S Orsola, Bologna, Italy; Mater Hosp, Brisbane, Australia; Peter MacCallum Cancer Ctr, Melbourne, Australia; St Mary's Hosp, Seoul, S Korea; Novartis Pharma AG, Basel, Switzerland

P130
The importance of iron stores in the chelation treatment of patients with myelodysplastic syndromes.
Medical University Center Hamburg-Eppendorf, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Children's Hospital & Research Center Oakland, USA

P131
Cost of transfusion-dependent myelodysplastic syndromes (MDS) in Germany.
Leibniz University Hannover, Centre for Health Economics, Hannover, Germany; Celgene GmbH, Munich, Germany; Innovation Oncology Research & Consulting (IORC) GmbH, Hamburg, Germany; University Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Centre for haematology and oncology, Düsseldorf, Germany

P132
Cost of transfusion dependency among managed care patients with myelodysplastic syndromes.
i3 Innovus, Eden Prairie, MN, USA; Duke University Medical Center, Durham, NC, USA

P133
Patients with myelodysplastic syndromes (MDS) challenge transfusion resources now and in the future.
C. Plesnila-Frank, K. Berger, A. Vioni-Niemeyer, W. Schramm
MERG-Medical Economics Research Group, Munich; Celgene GmbH, Munich; University of Munich, Dpt. of Transfusion Medicine and Haemostaseology, Munich, Germany

P134
Recombinant erythropoietin for transfusion-dependent myelodysplastic syndromes: long-term follow-up shows no modification of the natural history of treated patients and suggests a possible better prognosis for responders.
P. Musto, G. Pietrantuono, R. Guariglia, O. Villani, F. D’Auria, A. Falcone, G. Sanpaolo, A. Zonno
Hematology and Stem Cell Transplantation Units, CROB, Rionero in Vulture and * IRCCS “Casa Sollievo della Sofferenza”, S. Giovanni Rotondo, Italy

P135
Has treatment with EPO+/- G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? a comparison between French-EPO patients and the IMRAW database.
For the Groupe Francophone des myélodysplasies (GFM)

P136
Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need.
P137
Response to erythropoietin (EPO) with or without differentiating treatment with 13-cis-retinoic-acid and dihydroxylated vitamin d3 in myelodysplastic syndromes (MDS).
On behalf of the Piedmont MDS Registry, Alessandria, Italy

P138
Myelodysplastic syndromes patients treated with recombinant erythropoietin show improved immunological functions.
Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Department of Internal Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Tel Aviv University, Tel Aviv, Israel; and Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

P139
WT1 gene expression decreases during erythropoietic growth factor treatment in MDS patients.
E.N. Oliva, M. Comis, M. Cuzzola, M. Danova, B. Rovati, G. Spampinato, C. Rigolinio, A. Meliadò, P. Iacopino, F. Nobile
Hematology Unit, Centro Trapianti di Midollo Osseo, Az Osp “B-M-M”, Reggio Calabria, Univ S. Matteo, Cytometry and Cellular Therapies Unit, Pavia, Italy

P140
Factors predicting for a favorable response among patients with myelodysplastic syndromes treated with erythropoietin ± G-CSF.

P141
High dose darbepoetin Q3W, alone or in combination with peg-filgrastim, for myelodysplastic syndromes unresponsive to recombinant erythropoietin.
P142
Darbepoetin for the treatment of anemia of myelodysplastic syndromes: efficacy and quality of life.
Hematology Unit, Az Osp "B-M-M", Reggio Calabria; Dept of Hematology, "La Sapienza" Univ, Rome; Univ S.Matteo, Cytometry and Cellular Therapies Unit, Pavia; Studi di Bari Univ, Cattedra e Servizio di Ematologia, Bari, Oncohematology Unit, Az Osp, Catania. Hematology Institute, Univ of Naples Federico II, Naples, Italy

PASSI PERDUTI

18:00-19:30 Poster Sessions with wine & cheese
(session supported by an unrestricted educational grant from MSD)

SESSION VIII: Treatment II
Immunomodulatory Drugs, Hypomethylating Agents, Intensive Chemotherapy and Stem Cell Transplantation
Chairmen: E.P. Alessandrino, F. Ferrara

P143
Combination of erythropoietin and low-dose thalidomide for the management of anemia of low-grade myelodysplasia.
L. Leb, S. Khanani, J. Rooney, C. Seidler
Division of Hematology, Oncology Fallon Clinic and UMMS, Worcester, MA, USA

P144
Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS).
P145
A meta-analysis of the published studies and the long term results of a large personal experience form the basis for an appropriate use of thalidomide in myelodysplastic syndromes.
P. Musto
Units of Hematology and Stem Cell Transplantation, CROB, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (Pz), and IRCCS Casa Sollievo della Sofferenza, S. Giovanni Rotondo (Fg), Italy

P146
Disease progression in del(5q) MDS patients treated with lenalidomide: Analysis of risk factors and long term outcome in 44 patients.
A.A.N. Giagounidis, S. Haase, V. Lohrbacher, M. Heinsch, B. Schuran, C. Aul
St. Johannes Hospital, Medizinische Klinik II, Duisburg, Germany

P147
Management of haematological adverse events in MDS patients treated with lenalidomide.

P148
Management of non-haematological adverse events in MDS patients treated with lenalidomide.

P149
Treatment of high risk MDS and AML post-MDS with Azacytidine (AZA): Current results of the French ATU program.
Hôpital Avicenne, AP-HP, Université Paris XIII, Bobigny, France

P150
Karyotype does not predict response to azacitidine in patients with myelodysplastic syndrome.
Division of Hematology/Oncology, Western Pennsylvania Hospital, The Western Pennsylvania Cancer Institute, Pittsburgh, PA, USA
P151
Azacitidine in combination with epo+G-CSF and valproic acid rapidly determines hematological improvement in pretreated non responsive IPSS int-1 MDS patients.
V. Santini, A. Gozzi T. Lunghi, A. Bosi
UF Ematologia AOU Careggi Università di Firenze, Italy

P152
G-CSF increases hematological response and survival among patients with myelodysplasia treated with azacitidine.
E. Falke, J. M. Rossetti, DO, R. K. Shadduck, MD, R. B. Kaplan, MD, M. Kennedy, MD, R. Juvvadi, MD, W. Kramer, CRA, J. Lister, MD
Division of Hematology/Oncology, Western Pennsylvania Hospital. The Western Pennsylvania Cancer Institute. Pittsburgh, PA

P153
Clinical effects of 5-azacitidine five days/monthly schedule in three symptomatic low-risk (IPSS: 0-1) myelodysplastic patients.
Cattedra di Ematologia, USD-TMO Trapianti di Midollo per Adulti, Azienda “Spedali Civili”, Brescia

P154
Combination of fludarabine and cytarabine as induction treatment of poor prognosis myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia (sAML): a single centre experience.
A. Crotta, M. Tassara, J. Peccatori, C. Corti, F. Lunghi, M.T. Lupo Stangellini, M. Bregni, F. Ciceri, M. Bernardi
Haematology-Bone Marrow Transplant Unit San Raffaele Scientific Institute, Milan, Italy

P155
Combination of fludarabine and cytarabine as induction treatment of poor prognosis myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia (sAML): a single centre experience.
A. Crotta, M. Tassara, J. Peccatori, C. Corti, F. Lunghi, M.T. Lupo Stangellini, M. Bregni, F. Ciceri, M. Bernardi
Haematology-Bone Marrow Transplant Unit San Raffaele Scientific Institute, Milan, Italy

P156
Allogeneic stem cell transplantation in patients with poor prognosis myelodysplastic syndrome (MDS) or secondary acute myeloid leukaemia (sAML): results from a single centre experience.
M. Tassara, A. Crotta, J. Peccatori, A. Assanelli, C. Corti, E. Guggiani, M.T. Lupo Stangellini, P. Servida, A. Ruggeri, V. Calbi, F. Ciceri, M. Bernardi
Hematology-Bone Marrow Transplant Unit San Raffaele Scientific Institute (Milan)
P157
FLAMSA-RIC allogeneic transplantation yields superior results in myelodysplastic syndromes and secondary acute myelogenous leukemia.
C. Dobbelstein, E. Dammann, S. Buchholz, M. Stadler, C. Koenecke, E. Weissinger, B. Hertenstein, J. Krauter, M. Eder, A. Ganser
Department of Hematology, Hemostasis and Oncology, Hannover Medical School, Germany

P158
Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemia arising in patients treated for lymphoma or breast cancer on behalf of GITIL group.
Hematology, Fondazione IRCCS Istituto Tumori-University of Milano, Hematology University of Torino, Hematology San Raffaele Milano, Hematology H.S.Croce Cuneo, Hematology University of Bologna, Hematology-University Verona, Medical Oncology Fondazione IRCCS Istituto Tumori-University of Milano, Italy

P159
A reduced-intensity conditioning regimen for children with refractory cytopenia transplanted from an unrelated donor.
Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany

P160
Hematopoietic stem cell transplantation for childhood MDS/JMML with pre-transplant chemotherapy.
Department of Pediatrics and Hematopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea; Department of Pediatrics, Chungnam National University, Daejeon, Korea
Saturday, May 19, 2007

AUDITORIUM

8:30-10:30  Evidence-Based Treatment of Myelodysplastic Syndromes I
(session supported by an unrestricted educational grant from Janssen-Cilag)
Chairman: E. Estey

8:30-9:00  Which MDS patients are candidates for treatment with hematopoietic growth factors?
P. Fenaux

9:00-9:30  Which MDS patients are candidates for aggressive chemotherapy?
G. Sanz

9:30-10:00 Is traditional low dose chemotherapy (cytarabine/melphalan) still an option?
D.T. Bowen

10:00-10:30 Which MDS patients are candidates for treatment with decitabine?
M. Lübbert

EXHIBITION AREA

10:30-11:00  Coffee Break
11:00-12:45 Evidence-Based Treatment of Myelodysplastic Syndromes

Chairman: A. Bosi

11:00-11:30 Which MDS patients are candidates for treatment with azacitidine?
L.R. Silverman

11:30-12:00 Do histone deacetylase inhibitors have a place in the treatment of myelodysplastic syndromes?
S.D. Gore

12:00-12:45 Which MDS patients are candidates for transplantation?
T. De Witte

12:45 Closing Remarks

Chairmen: M. Cazzola, N. Zoumbos
General Information

Scientific Secretariat
Dr. Luca Malcovati, Dr. Matteo Della Porta
Tel. +39.0382.503062 Email: scientific.secretariat@mds2007.org

Meeting Location
Palazzo dei Congressi, Piazza Adua 1, 50123 Firenze (Florence), Italy.
The meeting venue is very close to the central railway station (Santa Maria Novella).

Registration
On site Registration fee is Euro 425,00.
The registration fee includes:
- conference kit
- participation in all scientific oral and poster sessions
- access to the exhibition area
- abstract book
- final program
- attendance certificate
- coffee breaks
- lunches May 17-18, 2007
- Welcome Reception in the Ammannati Courtyard, Palazzo Pitti - May 16, 2007 - 7,45 p.m.
- Social Dinner at Palazzo Corsini – May 18, 2007 - 8,30 p.m.
Continuing Medical Education (CME) Credits
The educational activity of 9th International Symposium on Myelodysplastic Syndromes has designated for a maximum of 19 credits for physicians and 18 credits for biologists by the Italian Ministry of Health (Ministero della Salute) within its CME Program.

An application, currently under evaluation, has been submitted to the European Hematology Association for a maximum of 21CME credits.

Social Program
The following social events are open to registered participants and included in the registration fee.

WEDNESDAY, MAY 16, 2007
7:45 p.m.  Welcome Reception in the Cortile Ammannati (Ammannati Courtyard), Palazzo Pitti

FRIDAY, MAY 18, 2007
8:30 p.m.  Social Dinner at Palazzo Corsini

REQUIRED INVITATION TICKET SHOULD BE COLLECTED AT REGISTRATION AREA WITHIN 17 MAY, 6.00 P.M.

Patient Forum
Saturday, May 19, 2007, from 1 p.m. to 4 p.m., at Palazzo degli Affari, meeting room II floor.
Piazza Adua 1, 50123 Firenze - Free entrance
Meeting organized under the auspices of:

Ferrata Storti Foundation, Pavia, Italy
SIE (Italian Society of Hematology)
SIES (Italian Society of Experimental Hematology)

Organizing Secretariat
Studio ER Congressi - Gruppo Triumph
Via Marconi 36 - 40122 Bologna, Italy
Tel: +39 051 4210559
Fax: +39 051 4210174
E-mail: ercongressi@gruppotriumph.it
Website: http://www.ercongressi.it

The Ninth International Symposium on Myelodysplastic Syndromes
Florence, Italy
May 16-19, 2007

Sponsored by The Myelodysplastic Syndrome Foundation, INC.
www.mds-foundation.org